SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies | Zendy

S. Momsen Reincke | Zendy; Meng Yuan | Zendy; HansChristian Kornau | Zendy; Victor M. Corman | Zendy; Scott van Hoof | Zendy; Elisa Sánchez-Sendín | Zendy; Melanie Ramberger | Zendy; Wenli Yu | Zendy; Yuanzi Hua | Zendy; Henry J. Tien | Zendy; Marie Luisa Schmidt | Zendy; Tatjana Schwarz | Zendy; Lara M. Jeworowski | Zendy; Sarah E. Brandl | Zendy; Helle Foverskov Rasmussen | Zendy; Marie A. Homeyer | Zendy; Laura Stöffler | Zendy; Martin Barner | Zendy; Désirée Kunkel | Zendy; Shufan Huo | Zendy; Johannes Horler | Zendy; Niels von Wardenburg | Zendy; Inge Kroidl | Zendy; Tabea M. Eser | Zendy; Andreas Wieser | Zendy; Christof Geldmacher | Zendy; Michael Höelscher | Zendy; Hannes Gänzer | Zendy; Günter Weiß | Zendy; Dietmar Schmitz | Zendy; Christian Drosten | Zendy; Harald Prüß | Zendy; Ian A. Wilson | Zendy; Jakob Kreye | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies

Author(s) -

S. Momsen Reincke,

Meng Yuan,

HansChristian Kornau,

Victor M. Corman,

Scott van Hoof,

Elisa Sánchez-Sendín,

Melanie Ramberger,

Wenli Yu,

Yuanzi Hua,

Henry J. Tien,

Marie Luisa Schmidt,

Tatjana Schwarz,

Lara M. Jeworowski,

Sarah E. Brandl,

Helle Foverskov Rasmussen,

Marie A. Homeyer,

Laura Stöffler,

Martin Barner,

Désirée Kunkel,

Shufan Huo,

Johannes Horler,

Niels von Wardenburg,

Inge Kroidl,

Tabea M. Eser,

Andreas Wieser,

Christof Geldmacher,

Michael Höelscher,

Hannes Gänzer,

Günter Weiß,

Dietmar Schmitz,

Christian Drosten,

Harald Prüß,

Ian A. Wilson,

Jakob Kreye

Publication year - 2022

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.abm5835

Subject(s) - antibody , virology , biology , neutralization , beta (programming language) , antigen , covid-19 , immunology , virus , medicine , disease , pathology , programming language , computer science , infectious disease (medical specialty)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant of concern (VOC) resists neutralization by major classes of antibodies from COVID-19 patients and vaccinated individuals. In this study, serum of Beta-infected patients revealed reduced cross-neutralization of wild-type virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of VOC-specific clonotypes and accommodation of mutations present in Beta and Omicron into a major antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with wild type–elicited antibodies, including a public VH1-58 clonotype that targets the RBD ridge. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift, with implications for design of next-generation vaccines and therapeutics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research